Skip to content
Dosage GuideResearch Reference

Angiotensin-(1-7) Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Angiotensin-(1-7). All information is for educational purposes only.

Quick Answer

Angiotensin-(1-7) is primarily administered intravenously in research settings due to its short half-life. Investigational subcutaneous formulations with cyclodextrin have shown promise. Dosing ranges from 0.03-0.3 mcg/kg/min IV or 50-500 mcg/kg subcutaneously, depending on the formulation and study goals. Oral delivery is under development.

→ Angiotensin-(1-7) Benefits→ Angiotensin-(1-7) Side Effects→ Full Angiotensin-(1-7) Profile
Table of Contents

Standard Dosage Range

Research dosing range: 0.03-0.3 mcg/kg/min (IV); 50-500 mcg/kg (subcutaneous)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Heart Failure (investigational)

0.1-0.3 mcg/kg/minContinuous IV infusion
Duration

24-72 hours

Used in hemodynamic studies to assess effects on cardiac output and pulmonary artery pressure. Requires close monitoring.

Pulmonary Hypertension (investigational)

50-250 mcg/kg1-2× daily
Duration

1-4 weeks

Subcutaneous administration of cyclodextrin-formulated Ang-(1-7). Aims to improve pulmonary vascular resistance and exercise capacity.

COVID-19 Related Lung Injury (investigational)

100-500 mcg/kg1-2× daily
Duration

7-14 days

Subcutaneous injection to counteract ACE2 downregulation and promote lung repair. Studied primarily in early-stage disease.

Diabetic Kidney Disease (investigational)

50-150 mcg/kg1× daily
Duration

8-12 weeks

Subcutaneous administration to reduce proteinuria and preserve glomerular filtration rate. Preclinical data is promising.

Timing & Frequency

Intravenous infusions are continuous. Subcutaneous injections are typically administered once or twice daily, with cyclodextrin formulations extending the peptide's half-life to approximately 30 minutes. Oral formulations are under development to improve bioavailability.

Cycle Guidance

Due to its investigational status, definitive cycle guidance is not established. Clinical trials have used durations ranging from days (IV) to weeks (subcutaneous). Continuous infusions require close medical supervision. Limited long-term safety data is available.

Reconstitution Reference

Quick reference for reconstituting Angiotensin-(1-7). For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeVaries (typically 1-5 mg)
BAC Water VolumeDependent on desired concentration
Concentration & DrawExample: 1 mg in 1 mL yields 1 mg/mL (1000 mcg/mL). Adjust volume to achieve target concentration.
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at -20°C.
StabilityReconstituted solution stable for a limited time (check manufacturer data). Lyophilized powder stable for 12-24 months.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical dosage range for Angiotensin-(1-7)?
The dosage varies based on the route of administration and the formulation. Intravenous infusions typically range from 0.03-0.3 mcg/kg/min. Subcutaneous injections using cyclodextrin formulations range from 50-500 mcg/kg per dose. Oral dosages are still under investigation.
How is Angiotensin-(1-7) administered?
Due to its short half-life, Angiotensin-(1-7) is often administered via continuous intravenous infusion in research settings. Subcutaneous injections with cyclodextrin formulations are also being explored to extend its activity. Oral formulations are in early clinical development.
What factors influence the dosage of Angiotensin-(1-7)?
The dosage is influenced by the route of administration, the specific formulation used (e.g., cyclodextrin-complexed), the individual's weight, and the condition being investigated. Close medical supervision is required, especially for intravenous infusions.
How often is Angiotensin-(1-7) administered?
Intravenous infusions are continuous. Subcutaneous injections are typically administered once or twice daily, depending on the specific study protocol and the formulation's half-life. Oral administration frequency is not yet established.
Is there an oral form of Angiotensin-(1-7) available?
While native Angiotensin-(1-7) is rapidly degraded orally, research is underway to develop oral formulations using cyclodextrin encapsulation to improve bioavailability. These formulations are still investigational.

References

  1. 1
    ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Therapeutic Perspective(2016)PubMed ↗
  2. 2
    Angiotensin-(1-7) in cardiovascular and pulmonary diseases(2014)PubMed ↗
  3. 3
    TXA127, a novel formulation of angiotensin (1-7)(2019)PubMed ↗

Last updated: 2026-02-19